Novartis remibrutinib trial data in Phase III RMS
TradingView reports Phase III RMS results for Novartis remibrutinib, an oral BTK inhibitor, citing reduced relapse rates and a favorable safety profile.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.